In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
New nasal spray stimulates ciliary activity in vitro Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351)Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Effect of diminazene on monocrotalin-induced pulmonary hypertension rat model Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013
Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Simulation of particle deposition in the human airways Source: Annual Congress 2013 –Airway calibre, airway challenge and assessment of oxygenation Year: 2013
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Development of a novel nano-sized carrier system for aeroseol drug delivery (EGE University translational pulmonology research group) Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013